Cancer Treatment Centers Of America Purchases Seventh Hyperthermia System From BSD Medical

BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced today that Cancer Treatment Centers of America (CTCA) at Southeastern Regional Medical Center has purchased a BSD-500 Hyperthermia System (BSD-500). CTCA Southeastern Regional Medical Center, located in the metropolitan Atlanta area, is a new 226,000-square-foot, all-digital hospital focused exclusively on treating cancer. CTCA Southeastern, which will open in August 2012, will provide the most innovative medical technologies available for cancer treatment (

CTCA is a network of hospitals that provides an unprecedented level of care to cancer patients. More than two-thirds of the patients are expected to come from outside the state of Georgia. Being a for-profit organization allows CTCA to invest profits in state-of-the-art technology, and CTCA has purchased BSD's hyperthermia systems for all of its sites. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as "offering the very best in cancer care."

"This will be the seventh BSD hyperthermia system purchased by CTCA, and we are excited to have another BSD system placed in these prestigious cancer care facilities," stated Harold Wolcott, BSD's President. “Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors. Hyperthermia is a non-invasive method of increasing tumor temperature to stimulate blood flow, increase oxygenation, and render tumor cells more sensitive to radiation. By adding hyperthermia to radiation therapy, physicians can increase local tumor control in certain tumors while minimizing damage to healthy tissue."

About the BSD-500 Hyperthermia System

The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the use of hyperthermia in conjunction with radiation therapy to treat certain tumors.

About Cancer Treatment Centers of America ®

Founded in 1988, Cancer Treatment Centers of America (CTCA) provide a comprehensive, patient-centered treatment model that fully integrates traditional, state-of-the-art medical treatments with scientifically supported complementary therapies to meet the special needs of advanced stage cancer patients. With a network of cancer treatment hospitals and community oncology programs in Arizona, Illinois, Oklahoma, Pennsylvania, Washington, and Georgia, CTCA is committed to revolutionizing cancer care by providing the most advanced and effective cancer treatments and supportive therapies available in order to treat the cancer and improve the patient’s treatment experience and quality of life. For more information about Cancer Treatment Centers of America, go to

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Copyright Business Wire 2010